Phase II Iressa Versus Vinorelbine (INVITE)

Exclusion Criteria

• •Newly diagnosed CNS metastases
• •Less than 4 weeks since completion of radiotherapy or persistence of any radiotherapy related toxicity.
• •Hypersensitivity to ZD1839 or intravenous vinorelbine
• •Prior treatment with EGFR inhibitors
• •Other co-existing malignancies
• •ALT/AST \>2.5 x ULRR
• •ANC \< 2.0 x 10\^9/L or platelets \< 100 x 10\^9/L